-
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
The New England Journal of Medicine, 2021
-
Efficacy and Safety of Weekly Paclitaxel With or Without Oral Alisertib in Patients With Metastatic Breast Cancer: A Randomized Clinical Trial
JAMA Network Open, 2021
-
Highlights in Early and Metastatic Breast Cancer From the 2020 San Antonio Breast Cancer Symposium: Commentary
Clinical Advances in Hematology & Oncology: H&O, 2021
-
Clinical Outcomes With Abemaciclib After Prior CDK4/6 Inhibitor Progression in Breast Cancer: A Multicenter Experience
Journal of the National Comprehensive Cancer Network: JNCCN, 2021
-
Sacituzumab Govitecan, a Trop-2-Directed Antibody-Drug Conjugate, for Patients With Epithelial Cancer: Final Safety and Efficacy Results From the Phase I/II IMMU-132-01 Basket Trial
Annals of Oncology: The Official Journal of the European Society for Medical Oncology, 2021
-
Optimal Strategies for Successful Initiation of Neratinib in Patients With HER2-Positive Breast Cancer
Clinical Breast Cancer, 2021
-
Recurrence Rates in Patients With HER2+ Breast Cancer Who Achieved a Pathological Complete Response After Neoadjuvant Pertuzumab Plus Trastuzumab Followed by Adjuvant Trastuzumab: A Real-World Evidence Study
Breast Cancer Research and Treatment, 2021
-
Baseline Characteristics and First-Line Treatment Patterns in Patients With HER2-Positive Metastatic Breast Cancer in the SystHERs Registry
Breast Cancer Research and Treatment, 2021
-
Reply to K. Hashimoto and A. Shimomura
Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 2021
-
Association of Immunophenotype With Pathologic Complete Response to Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: A Secondary Analysis of the BrighTNess Phase 3 Randomized Clinical Trial
JAMA Oncology, 2021
-
Neratinib in the Early-Stage/Extended Adjuvant Breast Cancer Patient: Q&A
Clinical Advances in Hematology & Oncology: H&O, 2020
-
Best Use of Neratinib in Patients With Early-Stage Breast Cancer
Clinical Advances in Hematology & Oncology: H&O, 2020
-
Neratinib in the Early-Stage/Extended Adjuvant Breast Cancer Patient
Clinical Advances in Hematology & Oncology: H&O, 2020
-
Neratinib: An Option for HER2-Positive Metastatic Breast Cancer–Q&A
Clinical Advances in Hematology & Oncology: H&O, 2020
-
Neratinib: Clinical Trial Data in HER2-Positive Metastatic Breast Cancer
Clinical Advances in Hematology & Oncology: H&O, 2020
-
Neratinib: An Option for HER2-Positive Metastatic Breast Cancer
Clinical Advances in Hematology & Oncology: H&O, 2020
-
Real-World Evidence of Diagnostic Testing and Treatment Patterns in US Patients With Breast Cancer With Implications for Treatment Biomarkers From RNA Sequencing Data
Clinical Breast Cancer, 2020
-
Prevalence of Germline BRCA Mutations in HER2-Negative Metastatic Breast Cancer: Global Results From the Real-World, Observational BREAKOUT Study
Breast Cancer Research: BCR, 2020
-
Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE)
Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 2020
-
Sacituzumab Govitecan in Previously Treated Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Final Results From a Phase I/II, Single-Arm, Basket Trial
Annals of Oncology: Official Journal of the European Society for Medical Oncology, 2020
-
Association of Pathologic Complete Response With Long-Term Survival Outcomes in Triple-Negative Breast Cancer: A Meta-Analysis
Cancer Research, 2020
-
Real-World Survival Outcomes of Heavily Pretreated Patients With Refractory HR+, HER2-Metastatic Breast Cancer Receiving Single-Agent Chemotherapy-A Comparison With MONARCH 1
Breast Cancer Research and Treatment, 2020
-
Evaluation of Pathologic Complete Response as a Surrogate for Long-Term Survival Outcomes in Triple-Negative Breast Cancer
Journal of the National Comprehensive Cancer Network: JNCCN, 2020
-
Efficacy of Eribulin for Metastatic Breast Cancer Based on Localization of Specific Secondary Metastases: A Post Hoc Analysis
Scientific Reports, 2020
-
Treatment Options for Patients With HR+/HER2- Advanced Breast Cancer During the COVID-19 Pandemic: Dose Reduction of Ribociclib Does Not Diminish Efficacy
Breast Cancer Research and Treatment, 2020
-
Patient-Derived Xenografts of Central Nervous System Metastasis Reveal Expansion of Aggressive Minor Clones
Neuro-oncology, 2020
-
Early Assessment With Magnetic Resonance Imaging for Prediction of Pathologic Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer: Results From the Phase III BrighTNess Trial
European Journal of Surgical Oncology: The Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2020
-
Baseline Characteristics, Treatment Patterns, and Outcomes in Patients With HER2-Positive Metastatic Breast Cancer by Hormone Receptor Status From SystHERs
Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 2020
-
Highlights in Metastatic Breast Cancer From the 2019 San Antonio Breast Cancer Symposium: Commentary
Clinical Advances in Hematology & Oncology: H&O, 2020
-
Pembrolizumab for Early Triple-Negative Breast Cancer
The New England Journal of Medicine, 2020
-
De Novo Versus Recurrent HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival From the SystHERs Registry
The Oncologist, 2020
-
Breast Conservation After Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: Surgical Results From the BrighTNess Randomized Clinical Trial
JAMA Surgery, 2020
-
Phase II Study of Eribulin Mesylate Administered Biweekly in Patients With Human Epidermal Growth Factor Receptor-2-Negative Metastatic Breast Cancer
Clinical Breast Cancer, 2020
-
Phase Ib Clinical Trial of the Anti-frizzled Antibody Vantictumab (OMP-18R5) Plus Paclitaxel in Patients with Locally Advanced or Metastatic HER2-negative Breast Cancer
Breast Cancer Research and Treatment, 2020
-
Neratinib: An Option for HER2-Positive Metastatic Breast Cancer–Q&A
Clinical Advances in Hematology & Oncology: H&O, 2020
-
Genomic Alterations Associated with Recurrence and TNBC Subtype in High-Risk Early Breast Cancers
Molecular Cancer Research: MCR, 2019
-
Pembrolizumab Monotherapy for Previously Treated Metastatic Triple-Negative Breast Cancer: Cohort A of the Phase II KEYNOTE-086 Study
Annals of Oncology: Official Journal of the European Society for Medical Oncology, 2019
-
Randomized Phase-II Evaluation of Letrozole Plus Dasatinib in Hormone Receptor Positive Metastatic Breast Cancer Patients
NPJ Breast Cancer, 2019
-
Trilaciclib Plus Chemotherapy Versus Chemotherapy Alone in Patients With Metastatic Triple-Negative Breast Cancer: A Multicentre, Randomised, Open-Label, Phase 2 Trial
The Lancet. Oncology, 2019
-
Health-Related Quality of Life in Patients Receiving First-Line Eribulin Mesylate With or Without Trastuzumab for Locally Recurrent or Metastatic Breast Cancer
BMC Cancer, 2019
-
Evaluation of Miracle Mouthwash Plus Hydrocortisone Versus Prednisolone Mouth Rinses As Prophylaxis for Everolimus-Associated Stomatitis: A Randomized Phase II Study
The Oncologist, 2019
-
Sacituzumab Govitecan-Hziy in Refractory Metastatic Triple-Negative Breast Cancer
The New England Journal of Medicine, 2019
-
Trilaciclib Plus Chemotherapy Versus Chemotherapy Alone in Patients With Metastatic Triple Negative Breast Cancer: A Multi-Centre, Randomised, Open-Label, Phase 2
The Lancet, 2019
-
Central Nervous System Metastasis in Patients With HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival From SystHERs
Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 2019
-
A Four-Gene Decision Tree Signature Classification of Triple-Negative Breast Cancer: Implications for Targeted Therapeutics
Molecular Cancer Therapeutics, 2019
-
Systematic Literature Review of Clinical Trials of Endocrine Therapies for Premenopausal Women With Metastatic HR+ HER2- Breast Cancer
The Breast Journal, 2019
-
Aberrant FGFR Signaling Mediates Resistance to CDK4/6 Inhibitors in ER+ Breast Cancer
Nature Communications, 2019
-
Perspectives on the Mechanism of Action and Clinical Application of Eribulin for Metastatic Breast Cancer
Future Oncology, 2019
-
Change in Topoisomerase 1-Positive Circulating Tumor Cells Affects Overall Survival in Patients With Advanced Breast Cancer After Treatment With Etirinotecan Pegol
Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 2018
-
Health-Related Quality of Life of Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer Treated With Ribociclib + Letrozole: Results From MONALEESA-2
Breast Cancer Research and Treatment, 2018
-
Updated Results From MONALEESA-2, a Phase III Trial of First-Line Ribociclib Plus Letrozole Versus Placebo Plus Letrozole in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
Annals of Oncology: Official Journal of the European Society for Medical Oncology, 2018
-
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Advanced HER2-Negative Breast Cancer and Elevated C-Reactive Protein, a Marker of Systemic Inflammation
Breast Cancer Research and Treatment, 2018
-
Nab-Paclitaxel Plus Carboplatin or Gemcitabine Versus Gemcitabine Plus Carboplatin As First-Line Treatment of Patients With Triple-Negative Metastatic Breast Cancer: Results From the tnAcity Trial
Annals of Oncology, 2018
-
Abstract PD1-01: Trilaciclib (T), a CDK4/6 Inhibitor, Dosed With Gemcitabine (G), Carboplatin (C) in Metastatic Triple Negative Breast Cancer (mTNBC) Patients: Preliminary Phase 2 Results
Cancer Research, 2018
-
Prognostic Characteristics in Hormone Receptor-Positive Advanced Breast Cancer and Characterization of Abemaciclib Efficacy
NPJ Breast Cancer, 2018
-
Development of Acquired Resistance to Lapatinib May Sensitise HER2-Positive Breast Cancer Cells to Apoptosis Induction by Obatoclax and TRAIL
BMC Cancer, 2018
-
Everolimus-Based Combination Therapies for HR+, HER2- Metastatic Breast Cancer
Cancer Treatment Reviews, 2018
-
IL1 Receptor Antagonist Controls Transcriptional Signature of Inflammation in Patients With Metastatic Breast Cancer
Cancer Research, 2018
-
Overall Survival in MERiDiAN, a Double-Blind Placebo-Controlled Randomised Phase III Trial Evaluating First-Line Bevacizumab Plus Paclitaxel for HER2-Negative Metastatic Breast Cancer
European Journal of Cancer, 2018
-
Ribociclib Plus Letrozole Versus Letrozole Alone in Patients With De Novo HR+, HER2- Advanced Breast Cancer in the Randomized MONALEESA-2 Trial
Breast Cancer Research and Treatment, 2018
-
Polyclonal RB1 Mutations and Acquired Resistance to CDK 4/6 Inhibitors in Patients With Metastatic Breast Cancer
Annals of Oncology: Official Journal of the European Society for Medical Oncology, 2018
-
Outcomes in Women With Invasive Ductal or Invasive Lobular Early Stage Breast Cancer Treated With Anastrozole or Exemestane in CCTG (NCIC CTG) MA.27
European Journal of Cancer, 2018
-
Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer
Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 2018
-
Nab-Paclitaxel Plus Carboplatin or Gemcitabine Versus Gemcitabine Plus Carboplatin As First-Line Treatment of Patients With Triple-Negative Metastatic Breast Cancer: Results From the tnAcity Trial
Annals of Oncology: Official Journal of the European Society for Medical Oncology, 2018
-
Ixabepilone and Carboplatin for Hormone Receptor Positive/HER2-Neu Negative and Triple Negative Metastatic Breast Cancer
Clinical Breast Cancer, 2018
-
Addition of the PARP Inhibitor Veliparib Plus Carboplatin or Carboplatin Alone to Standard Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer (BrighTNess): A Randomised, Phase 3 Trial
The Lancet. Oncology, 2018
-
Five-Year Results of a Phase II Trial of Preoperative 5-Fluorouracil, Epirubicin, Cyclophosphamide Followed by Docetaxel With Capecitabine (wTX) (With Trastuzumab in HER2-Positive Patients) for Patients With Stage II or III Breast Cancer
Cancer Medicine, 2018
-
Hybrid Capture-Based Genomic Profiling of Circulating Tumor DNA From Patients With Estrogen Receptor-Positive Metastatic Breast Cancer
Annals of Oncology: Official Journal of the European Society for Medical Oncology, 2017
-
MONARCH 1, a Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients With Refractory HR(+)/HER2(-) Metastatic Breast Cancer
Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 2017
-
Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06–090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology)
Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 2017
-
Comparative Efficacy and Safety of Adjuvant Letrozole Versus Anastrozole in Postmenopausal Patients With Hormone Receptor-Positive, Node-Positive Early Breast Cancer: Final Results of the Randomized Phase III Femara Versus Anastrozole Clinical Evalua
Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 2017
-
Comparative Efficacy and Safety of Adjuvant Letrozole Versus Anastrozole in Postmenopausal Patients With Hormone Receptor-Positive, Node-Positive Early Breast Cancer: Final Results of the Randomized Phase III Femara Versus Anastrozole Clinical Evalua
Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 2017
-
Erratum To: Prolonged Survival in Patients With Breast Cancer and a History of Brain Metastases: Results of a Preplanned Subgroup Analysis From the Randomized Phase III BEACON Trial
Breast Cancer Research and Treatment, 2017
-
MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2- Metastatic Breast Cancer
Clinical Cancer Research, 2017
-
Bevacizumab Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for HER2-Negative Metastatic Breast Cancer (MERiDiAN): A Double-Blind Placebo-Controlled Randomised Phase III Trial With Prospective Biomarker Evaluation
European Journal of Cancer, 2017
-
A Randomized Adaptive Phase II/III Study of Buparlisib, a Pan-Class I PI3K Inhibitor, Combined With Paclitaxel for the Treatment of HER2- Advanced Breast Cancer (BELLE-4)
Annals of Oncology: Official Journal of the European Society for Medical Oncology, 2017
-
Prolonged Survival in Patients With Breast Cancer and a History of Brain Metastases: Results of a Preplanned Subgroup Analysis From the Randomized Phase III BEACON Trial
Breast Cancer Research and Treatment, 2017
-
Enrichment of PI3K-AKT-mTOR Pathway Activation in Hepatic Metastases From Breast Cancer
Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 2017
-
Health-Related Quality of Life in Patients With Locally Recurrent or Metastatic Breast Cancer Treated With Etirinotecan Pegol Versus Treatment of Physician’s Choice: Results From the Randomised Phase III BEACON Trial
European Journal of Cancer, 2017
-
Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer
Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 2017
-
A Preclinical Evaluation of the MEK Inhibitor Refametinib in HER2-Positive Breast Cancer Cell Lines Including Those With Acquired Resistance to Trastuzumab or Lapatinib
Oncotarget, 2017
-
Hybrid Capture-Based Genomic Profiling of Circulating Tumor DNA From Patients With Estrogen Receptor-Positive Metastatic Breast Cancer
Annals of Oncology: Official Journal of the European Society for Medical Oncology, 2017
-
Eribulin Mesylate with Trastuzumab as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2)-Positive Breast Cancer: Preliminary Results from a Phase 2, Multicenter, Single-Arm Study
35th Annual San Antonio Breast Cancer Symposium, 2012
-
Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer
New England Journal of Medicine, 2011
-
Phase 2 Study of Weekly Nab-Paclitaxel for the Treatment of Patients With Metastatic Breast Cancer Heavily Pretreated With Taxanes
Clinical Breast Cancer, 2007
-
Capecitabine/Taxane Combination Therapy: Evolving Clinical Utility in Breast Cancer
Clinical Breast Cancer, 2006
-
Phase II Trial of Capecitabine and Weekly Paclitaxel As First-Line Therapy for Metastatic Breast Cancer
Journal of Clinical Oncology, 2006
-
Results of a Phase III Trial Doxoroubicin/Cyclophosphamide (AC) Compared to Docetaxel/Cyclophosphamide (TC) As Adjuvant Therapy for Operable Breast Cancer
Journal of Clinical Oncology, 2006
-
Are Granulocyte Colony-Stimulating Growth Factors (CSF’s) Needed to Prevent Febrile Neutropenia (FN) for Course #1 of Adjuvant Chemotherapy With “Standard” Doxorubicin-Cyclophosphamide (ASC) Results From Two Consecutive US Oncology Community Adjuvant
Breast Cancer Research and Treatment, 2006
-
A Randomized, Multicenter Phase III Trial Comparing Regimens of Doxorubicin + Cyclophosphamide Followed by Paclitaxel or Doxorubicin + Paclitaxel Followed by Weekly Paclitaxel As Adjuvant Therapy for Patients With High Risk Breast Cancer
Breast Cancer Research and Treatment, 2004